Table 1.
Comparison of the number of patients having more markers with therapy options from the VMTB report versus the commercial lab test report
| Therapy recommendations | # of patients |
Test of proportions: Null hypothesis is that percentage of patients with more markers from VMTB report = 50% | ||
|---|---|---|---|---|
| More markers from VMTB report (percentage) | More markers from commercial lab test report (percentage) | Total assigned to specific therapy recommendations | ||
| Off-label | 171 | 50 | 221 | 6.9 × 10−16 |
| (77%) | (23%) | |||
| Clinical trial | 496 | 129 | 625 | 1.6 × 10−48 |
| (79%) | (21%) | |||
| Any therapy | 503 | 139 | 642 | 1.5× 10−46 |
| (On-label/Off-label/Clinical trial) | (78%) | (22%) | ||
Note: The number of patients having more markers with therapy options from the VMTB report, compared to the commercial lab test report for either off-label, clinical trial, or any therapy option. Note that the total number of patients within this cohort considered is 642, out of which all have at least one marker with a therapy recommendation, but only 221 have markers with off-label indications and 625 have markers with clinical trials indications. The rightmost column gives the p-value from a test of proportions comparing the fraction of patients with more markers from the VMTB report (vs the commercial lab test report) to 0.5, using the prop.test function in the R statistical programming language.